A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Join Chris Palmer, chief creative officer, BGB Group, and Jameson Fleming, editor-in-chief, MM+M, live from Cannes as they discuss trends, AI and inspiration.

How much would you pay for a limited-edition new wearable product? If you’re anything like this engineer: a pretty penny.

The latest news and headlines from Yahoo News. Get breaking news stories and in-depth coverage with videos and photos.